Stability of plasma anti-Xa activity in low-molecular-weight heparin monitoring

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 3, 2010, Pages 313-317

  Rojnuckarin, Ponlapat ^a   Akkawat, Benjaporn ^a   Juntiang, Jumlong ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Factor Xa; In vitro diagnostic systems; Inhibitors; Low molecular weight heparins

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; ENVIRONMENTAL TEMPERATURE; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MONITORING; MORBID OBESITY; PRIORITY JOURNAL; ROOM TEMPERATURE; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD PRESERVATION; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; ENOXAPARIN; FACTOR XA; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; INFANT; KIDNEY DISEASES; MALE; MIDDLE AGED; OBESITY, MORBID; PROSPECTIVE STUDIES; PROTEIN STABILITY; SPECIMEN HANDLING; TEMPERATURE; THROMBOPHILIA; YOUNG ADULT;

EID: 77953633332     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609336853     Document Type: Article

References (15)

1. Büller HR, Agnelli G., Hull RD, Hyers TM, Prins MH, Raskob GE Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126 (3 suppl). 401S - 428S.
2. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004 ; 4: CD001100.
3. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 ; 349 (2). 146-153.
4. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005 ; 23 (10). 2123-2129.
5. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005 ; 23 (10). 2130-2135.
6. Lim W., Dentali F., Eikelboom JW, Crowther MA Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006 ; 144 (9). 673-684.
7. Hirsh J., Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126 (3 suppl). 188S - 203S. (Pubitemid 39297954)
8. Dade Behring Inc. Berichrom* Heparin Anti-Xa assay User Manual, Ed. March 2006.
9. Hamilton MA, Stang L., Etches WS, Rennie R., Mant MJ Stability of low molecular weight heparins stored in plastic syringes. Thromb Res. 2003 ; 112 (1-2). 117-119.
10. Laposata M., Johnson SM Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days: an in vitro study. Clin Ther. 2003 ; 25 (4). 1219-1225.
11. Charland SL, Davis DD, Tillman DJ Activity of enoxaparin sodium in tuberculin syringes for 10 days. Am J Health Syst Pharm. 1998 ; 55 (12). 1296-1298.
12. Dager WE, Gosselin RC, King JH, Christensen CL, Owings JT, Larkin EC Anti-Xa stability of diluted enoxaparin for use in pediatrics. Ann Pharmacother. 2004 ; 38 (4). 569-573.
13. Nowak-Göttl U., Bidlingmaier C., Krümpel A., Göttl L., Kenet G. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children. Br J Pharmacol. 2008 ; 153 (6). 1120-1127.
14. O'Brien SH, Lee H., Ritchey AK Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study. J Thromb Haemost. 2007 ; 5 (9). 1985-1987.
15. Sutor AH, Chan AK, Massicotte P. Low-molecular-weight heparin in pediatric patients. Semin Thromb Hemost. 2004 ; 30 (suppl 1). 31-39.